Altria reported fourth-quarter results showing adjusted EPS growth of 3.5% year-over-year, driven by a 6.2% increase in average selling prices that more than offset a 4% decline in shipment volumes for its smokeable products. Total revenue remained essentially flat at $6.4 billion, reflecting strong pricing power in the face of a 2.1% industrywide volume contraction. Management noted that Marlboro’s market share held steady at 39.8% despite ongoing secular headwinds, while the oral tobacco and nicotine pouch segment delivered modest revenue growth of 0.9%. Operating margin for the smokeable segment expanded by 120 basis points, reinforcing the company’s ability to protect profitability through disciplined cost management and targeted price increases.

The company returned $2.6 billion to shareholders in the quarter, including $1.8 billion in share repurchases and $805 million in dividends, maintaining a dividend yield near 7%. Leverage remains conservative, with net debt to EBITDA of 2.9x at year-end, well within the board’s target range of 2.5–3.5x. Management reiterated guidance for annual adjusted free cash flow of $6.5–$7.0 billion through 2028, supporting a projected dividend growth rate of 4–5% per annum. Progress on smoke-free products accelerated with the US FDA granting marketing authorization for the company’s nicotine pouch brand in December, expected to contribute incremental revenue of $200–$250 million in 2026 following recent acquisitions in Europe and Canada.

Following the release of full-year 2025 results, two major brokerages upgraded their ratings to Buy, citing clarity on earnings trajectories and continued shareholder returns. One firm noted that valuation multiples have re-rated to 9.5x forward P/E, reflecting discounted levels last seen in mid-2023, while another maintained a Hold rating due to limited upside beyond dividend income given the 87.5% revenue concentration in legacy tobacco. Consensus estimates project adjusted EPS compound annual growth of 5% and total shareholder return of 8–10% over the next 12 months, assuming sustained pricing initiatives and incremental gains in the smoke-free portfolio.